Biotech RadarJobs updated

COMPANY

Ankyra Therapeutics

HQ: Cambridge, MA source · ankyratx.com ↗ · New England

Clinical Phase 1

Keywords: oncology immunology Non Small Cell Lung Cancer Cutaneous Squamous Cell Carcinoma Renal Transplant Solid Tumor Cancer Cutaneous Tumor Subcutaneous Tumor Metastasis to Soft Tissue tolododekin alfa

Location: Cambridge, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

3Trials (company is sponsor)

Timeline

  1. Trial start Phase 1: A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma source ↗
  2. Trial start Phase 1: A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer source ↗
  3. Partnership Partnership / licensing announced Jan 10, 2025. Source: company's own press page. source ↗
  4. Trial start I: Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Clinical trials (lead sponsor) 3

RecordTitlePhaseStatusStartPrimary completion
NCT07027514A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung CancerPhase 1RecruitingOct 22, 2025Jun 30, 2027 (estimated)
NCT07100925A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell CarcinomaPhase 1WithdrawnDec 15, 20252030-06 (estimated)
NCT06171750Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid TumorsIRecruitingJan 19, 20242027-04 (estimated)
Feedback